Unjha Formul.

{
  "main_header": {
    "sid": 782664,
    "name": "Unjha Formul.",
    "stock_name": "Unjha Formul.",
    "full_name": "Unjha Formulations Ltd",
    "name_url": "stocks-analysis/unjha-formul",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "22.14",
    "chg": 0.28,
    "chgp": "1.28%",
    "dir": 1,
    "prev_price": "21.86",
    "mcapval": "10.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531762,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE576D01015",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "2.23 k",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/unjha-formul-782664-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Unjha Formulations Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-unjha-formulations-ltd-fallingrising-3790682",
        "imagepath": "",
        "date": "2026-01-14 00:41:31",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Intraday Price Movement and Volatility</strong></p>\n<p>On the day in question, the stock opened with a gap up of 3.75%, reaching an intraday high of ₹24.90, signalling initial optimism among investors. However, this positive momentum was short-lived as the share price plunged to an intraday low of ₹21.62, representing a decline of nearly 9.92% from the opening price. The stock traded within a wide range of ₹3.28, reflecting high volatility with an intraday volatility measure of 7.05%. Notably, the weighted average price indicated that more volume was traded closer to the lower end of the price range, suggesting selling pressure dominated the session.</p>\n<p>Adding to the bearish sentiment, Unjha Formulations is currently trading below all key moving averages, including the 5-day, 20-day, 50-..."
      },
      {
        "title": "Unjha Formulations Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-ltd-upgraded-to-hold-as-technicals-improve-amid-mixed-financials-3774325",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/UnjhaFormulatio_mojoScore_3774325.png",
        "date": "2025-12-30 08:18:51",
        "description": "Unjha Formulations Ltd has seen its investment rating upgraded from Sell to Hold as of 29 December 2025, reflecting a nuanced improvement across technical indicators, valuation metrics, and recent financial performance. Despite lingering challenges in long-term fundamentals and market underperformance, the company’s evolving technical trend and attractive valuation have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Unjha Formulations Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-ltd-is-rated-sell-3768649",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/UnjhaFormulatio_mojoScore_3768649.png",
        "date": "2025-12-24 20:23:06",
        "description": "Unjha Formulations Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Unjha Formulations Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-downgraded-to-sell-amid-mixed-financial-and-technical-signals-3740563",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/UnjhaFormulatio_mojoScore_3740563.png",
        "date": "2025-12-02 08:19:35",
        "description": "Unjha Formulations, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by a combination of technical trends, valuation metrics, financial performance, and broader market returns. This article analyses the key factors influencing the recent revision in the company’s evaluation, providing investors with a comprehensive understanding of the current landscape."
      },
      {
        "title": "How has been the historical performance of Unjha Formul.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-unjha-formul-3739206",
        "imagepath": "",
        "date": "2025-12-01 23:06:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Performance Trends</strong></p>\n<p>Over the past seven years, Unjha Formul.'s net sales have demonstrated notable volatility. The company recorded a peak in total operating income in the fiscal year ending March 2024, followed by a decline in the subsequent year. Earlier years showed moderate growth from fiscal 2019 to 2021, with sales rising from just over ₹11 crores to nearly ₹10 crores, before surging to above ₹18 crores in 2024. However, the latest fiscal year saw a contraction to under ₹14 crores, indicating challenges in sustaining top-line momentum.</p>\n<p>Raw material costs have consistently represented the largest expenditure, closely tracking revenue fluctuations. These costs peaked alongside sales in 2024 but decreased in line with the revenue dip in 2025. Em..."
      },
      {
        "title": "Why is Unjha Formul. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-unjha-formul-fallingrising-3716043",
        "imagepath": "",
        "date": "2025-11-19 22:09:44",
        "description": "As of 19-Nov, Unjha Formulations Ltd is currently priced at 26.40, reflecting an increase of 0.7, or 2.72%. The stock has shown strong performance in the short term, with a 1-week return of 6.02% and a 1-month return of 9.91%, both significantly outperforming the Sensex, which returned 0.85% and 1.47% respectively. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend. However, there has been a notable decline in investor participation, with delivery volume dropping by 83.62% compared to the 5-day average, which could raise concerns about the sustainability of the recent price increase. There are no specific positive or negative factors available to further explain the stock's recent movement.\n\nBroader Market Context: In the context of the broader market, Unjha Formulations Ltd's recent short-term performance stands out, particu..."
      },
      {
        "title": "Why is Unjha Formul. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-unjha-formul-fallingrising-3698550",
        "imagepath": "",
        "date": "2025-11-13 22:02:09",
        "description": "As of 13-Nov, Unjha Formulations Ltd is experiencing a price increase, with its current price at Rs 26.99, reflecting a rise of Rs 2.09 or 8.39%. The stock opened with a gain of 2.29% today and reached an intraday high of Rs 27.5, marking a 10.44% increase. Additionally, Unjha Formulations has outperformed its sector by 8.18%. Over the past week, the stock has shown a significant return of +17.40%, while its performance over the last month is +10.98%. However, there has been a decline in investor participation, with delivery volume dropping by 17.42% compared to the 5-day average, which may indicate a potential concern for sustained momentum.\n\nBroader Market Context: In comparison to the benchmark Sensex, which has increased by 1.40% over the past week and 2.61% over the past month, Unjha Formulations has significantly outperformed in the short term. Despite a year-to-date decline of 11.19% against the Sens..."
      },
      {
        "title": "Unjha Formulations Reports Strong Financial Performance Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-financial-trend-improves-from-negative-to-positive-amid-strong-performance-metrics-3697424",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/UnjhaFormulatio_fintrenddot_3697424.png",
        "date": "2025-11-13 11:03:26",
        "description": "Unjha Formulations has reported strong financial performance for the quarter ending September 2025, achieving record figures in key metrics such as PBDIT, PBT, and PAT. The company's stock has shown volatility, with notable fluctuations in price, while long-term returns have significantly outperformed the Sensex."
      },
      {
        "title": "Unjha Formulations Q2 FY26: Micro-Cap Pharma Posts Highest Quarterly Profit Despite Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/unjha-formulations-q2-fy26-micro-cap-pharma-posts-highest-quarterly-profit-despite-valuation-concerns-3698424",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/UnjhaFormulatio_quaterlyResult_3698424.png",
        "date": "2025-11-13 09:35:42",
        "description": "Unjha Formulations Ltd., a Gujarat-based micro-cap pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported its highest-ever quarterly net profit of ₹0.82 crores in Q2 FY26, marking a substantial turnaround from previous quarters. The company's net profit surged 110.26% quarter-on-quarter (QoQ) and reversed from a loss of ₹0.11 crores in Q2 FY25, representing a year-on-year (YoY) swing into profitability. However, despite these improved operational metrics, the stock trades at a \"Very Expensive\" valuation with a market capitalisation of just ₹11.00 crores, raising questions about sustainability and investor expectations."
      }
    ],
    "total": 128,
    "sid": "782664",
    "stock_news_url": "https://www.marketsmojo.com/news/unjha-formulations-782664"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "12-Jan-2026",
      "details": "As per regulation 74(5) of SEBI(dp) Regulation 2018",
      "source": "BSE"
    },
    {
      "caption": "Publish Un-Audited Financial Results For The Quarter & Half Year Ended As On 30/09/2025",
      "datetime": "12-Nov-2025",
      "details": "Regulation 33(3) of SEBI (LODR)Act 2015",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for : Approval Of Un-Audited Financial Results Of The Company For Quarter Ended And Half Year Ended On 30Th September2025 And Out Come Of Board Meeting Held On 10Th November 2025",
      "datetime": "10-Nov-2025",
      "details": "REGULATION 33 OF SEBI LODR 2015.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Unjha Formulations Ltd falling/rising?

2026-01-14 00:41:31

Intraday Price Movement and Volatility

On the day in question, the stock opened with a gap up of 3.75%, reaching an intraday high of ₹24.90, signalling initial optimism among investors. However, this positive momentum was short-lived as the share price plunged to an intraday low of ₹21.62, representing a decline of nearly 9.92% from the opening price. The stock traded within a wide range of ₹3.28, reflecting high volatility with an intraday volatility measure of 7.05%. Notably, the weighted average price indicated that more volume was traded closer to the lower end of the price range, suggesting selling pressure dominated the session.

Adding to the bearish sentiment, Unjha Formulations is currently trading below all key moving averages, including the 5-day, 20-day, 50-...

Read full news article

Unjha Formulations Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financials

2025-12-30 08:18:51

Unjha Formulations Ltd has seen its investment rating upgraded from Sell to Hold as of 29 December 2025, reflecting a nuanced improvement across technical indicators, valuation metrics, and recent financial performance. Despite lingering challenges in long-term fundamentals and market underperformance, the company’s evolving technical trend and attractive valuation have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Read full news article

Unjha Formulations Ltd is Rated Sell

2025-12-24 20:23:06

Unjha Formulations Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Unjha Formulations Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-02 08:19:35

Unjha Formulations, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by a combination of technical trends, valuation metrics, financial performance, and broader market returns. This article analyses the key factors influencing the recent revision in the company’s evaluation, providing investors with a comprehensive understanding of the current landscape.

Read full news article

How has been the historical performance of Unjha Formul.?

2025-12-01 23:06:41

Revenue and Operating Performance Trends

Over the past seven years, Unjha Formul.'s net sales have demonstrated notable volatility. The company recorded a peak in total operating income in the fiscal year ending March 2024, followed by a decline in the subsequent year. Earlier years showed moderate growth from fiscal 2019 to 2021, with sales rising from just over ₹11 crores to nearly ₹10 crores, before surging to above ₹18 crores in 2024. However, the latest fiscal year saw a contraction to under ₹14 crores, indicating challenges in sustaining top-line momentum.

Raw material costs have consistently represented the largest expenditure, closely tracking revenue fluctuations. These costs peaked alongside sales in 2024 but decreased in line with the revenue dip in 2025. Em...

Read full news article

Why is Unjha Formul. falling/rising?

2025-11-19 22:09:44

As of 19-Nov, Unjha Formulations Ltd is currently priced at 26.40, reflecting an increase of 0.7, or 2.72%. The stock has shown strong performance in the short term, with a 1-week return of 6.02% and a 1-month return of 9.91%, both significantly outperforming the Sensex, which returned 0.85% and 1.47% respectively. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend. However, there has been a notable decline in investor participation, with delivery volume dropping by 83.62% compared to the 5-day average, which could raise concerns about the sustainability of the recent price increase. There are no specific positive or negative factors available to further explain the stock's recent movement. Broader Market Context: In the context of the broader market, Unjha Formulations Ltd's recent short-term performance stands out, particu...

Read full news article

Why is Unjha Formul. falling/rising?

2025-11-13 22:02:09

As of 13-Nov, Unjha Formulations Ltd is experiencing a price increase, with its current price at Rs 26.99, reflecting a rise of Rs 2.09 or 8.39%. The stock opened with a gain of 2.29% today and reached an intraday high of Rs 27.5, marking a 10.44% increase. Additionally, Unjha Formulations has outperformed its sector by 8.18%. Over the past week, the stock has shown a significant return of +17.40%, while its performance over the last month is +10.98%. However, there has been a decline in investor participation, with delivery volume dropping by 17.42% compared to the 5-day average, which may indicate a potential concern for sustained momentum. Broader Market Context: In comparison to the benchmark Sensex, which has increased by 1.40% over the past week and 2.61% over the past month, Unjha Formulations has significantly outperformed in the short term. Despite a year-to-date decline of 11.19% against the Sens...

Read full news article

Unjha Formulations Reports Strong Financial Performance Amid Market Volatility

2025-11-13 11:03:26

Unjha Formulations has reported strong financial performance for the quarter ending September 2025, achieving record figures in key metrics such as PBDIT, PBT, and PAT. The company's stock has shown volatility, with notable fluctuations in price, while long-term returns have significantly outperformed the Sensex.

Read full news article

Unjha Formulations Q2 FY26: Micro-Cap Pharma Posts Highest Quarterly Profit Despite Valuation Concerns

2025-11-13 09:35:42

Unjha Formulations Ltd., a Gujarat-based micro-cap pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported its highest-ever quarterly net profit of ₹0.82 crores in Q2 FY26, marking a substantial turnaround from previous quarters. The company's net profit surged 110.26% quarter-on-quarter (QoQ) and reversed from a loss of ₹0.11 crores in Q2 FY25, representing a year-on-year (YoY) swing into profitability. However, despite these improved operational metrics, the stock trades at a "Very Expensive" valuation with a market capitalisation of just ₹11.00 crores, raising questions about sustainability and investor expectations.

Read full news article

View All News